EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2197-2204

  Su, Nai Wen ^a   Leu, Yi Shing ^a   Lee, Jehn Chuan ^a   Liu, Chung Ji ^a   Cheng, Chieh Yuan ^a   Lin, Jiun Sheng ^a   Chen, Yu Jen ^a   Chen, Chi Kuan ^a   Fang, I Chih ^a   Hsieh, Ruey Kuen ^a   Chang, Yi Fang ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Biomarker; EGF A61G; EGFR R521K; Head and neck cancer; Polymorphisms

Indexed keywords

ADENINE; CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GUANINE; UFT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LARYNX SQUAMOUS CELL CARCINOMA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH TUMOR; MULTIVARIATE ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; OVERALL SURVIVAL; PHARYNX CARCINOMA; POSTOPERATIVE CARE; PREDICTION; PRIMARY TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

EID: 84919391192     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S70188     Document Type: Article

References (40)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1698–1709.
2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944.
3. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–1952.
4. Psyrri A, Licitra L, Lacombe D, et al. Strategies to promote translational research within the European Organization for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. Ann Oncol. 2010;21(10): 1952–1960.
5. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21): 3582–3589.
6. Ciardiello F, Tortoa G. EGFR antagonist in cancer treatment. N Engl J Med. 2008;358(11):1160–1174.
7. Ciardiello F, Tortoa G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958–2970.
8. Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012;72(12):2924–2930.
9. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354.
10. Sheikh MS, Carrier F, Johnson AC, Ogdon SE, Fornace AJ Jr. Identification of an additional p53-responsive site in humen epidermal growth factor gene promotor. Oncogene. 1997;15(9):1095–1101.
11. Psyrri A, Yu Z, Weingerger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oral squamous cell carcinoma by using automated quantitative analysis. Clin Cancer Res. 2005;11(16):5856–5862.
12. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579–3584.
13. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J. Expression of protein tyrosine kinase in head and neck squamous cell carcinoma. Am J Clin Pathol. 2005;124(1):71–76.
14. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824–832.
15. Lanuti M, Liu G, Goodwin JM, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum level, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res. 2008; 14(10): 3216–3222.
16. Tanabe KK, Lemoine A, Finkelstein DM, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008;299(1):53–60.
17. Xu X, Xi L, Zeng J, Yao Q. A functional +61G/A polymorphism in epidermal growth factor is associated with glioma risk among Asians. PLoS One. 2012;7(7):e41470.
18. Leite MS, Giacomin LC, Piranda DN, et al. Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer. BMC Cancer. 2014;14:190.
19. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2001;359(9304):397–401.
20. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 2004;64(4):1220–1223.
21. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered typeαtransforming growth factor binding and transmembrane signaling. Pro Natl Acad Sci USA. 1994;91(21):10217–10221.
22. Liu W Innocenti F, Wu MH, et al. A functional common polymorphism in a spl recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005;65(1):46–53.
23. Gram Spindler KL, Nielsen JN, Lindebjerg J, Brandslund l, Jakobsen A. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys. 2006;66(2):500–504.
24. Wang WS, Chen PM, Chiou TJ, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res. 2007;13(12):3597–3604.
25. Bandres E, Barricarte R, Cantero C, et al. Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncol. 2007;43(7):713–719.
26. Liu G, Gurubhaqavatula S, Zhou W, et al. Epidermal growth factor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008;8(2):129–138.
27. Han SW, Oh DY, Im SA, et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 2010;101(3):793–799.
28. McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer. 2003;107(4):673–675.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578.
30. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11): 1116–1127.
31. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765.
32. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXETREME study. Ann Oncol. 2011;22(5):1078–1087.
33. Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710.
34. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial. And relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28.
35. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol. 2008;26(9):1427–1434.
36. Lurje G, Nagashima F, Zhang W, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008;14(23):7884–7895.
37. Garm Spindler KL, Pallosgaard N, Rasmussen AA, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009;20(5):879–884.
38. Hsieh YY, Tzeng CH, Chen PM, Wang WS. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. Cancer Sci. 2012;103(4):791–796.
39. Klinghammer K, Knodler M, Schmittel A, Budach V, Keilholz U, Tinhofer I. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximan-docetaxel treatment. Clin Cancer Res. 2010;16(1):304–310.
40. Stoehlmacher-Williams J, Obermann L, Ehninger G, Goekkurt E. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC). Anticancer Res. 2012;32(2):421–426.